SCHEMBL30734142

SCHEMBL30734142

Nc1cc(-c2ccc3ncnc(N4CCN(c5ccc(O)cc5)CC4)c3n2)ccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 10/20 0.44
PIM1 P11309 1/20 0.44
PIM3 Q86V86 1/20 0.44
PIM2 Q9P1W9 1/20 0.44
MINK1 Q8N4C8 1/20 0.44
TNIK Q9UKE5 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
ALDH1A1 P00352 2/20 0.43
GAA P10253 2/20 0.43
MAPT P10636 2/20 0.43
MCL1 Q07820 2/20 0.43
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ROCK2 O75116 1/20 0.41
ROCK1 Q13464 1/20 0.41
MKNK1 Q9BUB5 2/20 0.38
MKNK2 Q9HBH9 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30734178 0.89 MAP4K4 (0.49) MAP4K4PIM1PIM3PIM2MINK1
SCHEMBL30734141 0.89 MAP4K4 (0.46) MAP4K4PIM1PIM3PIM2MINK1
SCHEMBL30734232 0.83 ALDH1A1 (0.49) MEN1KMT2AALDH1A1GAAMAPT
SCHEMBL30734219 0.81 ACHE (0.47) MAP4K4MINK1TNIKMEN1KMT2A
SCHEMBL30734199 0.79 MAP4K4 (0.47) MAP4K4MINK1TNIKMAPTSMN1; SMN2
SCHEMBL30734209 0.76 MAP4K4 (0.47) MAP4K4MINK1TNIKALDH1A1MAPT
SCHEMBL31745185 0.75 PIM1 (0.44) MAP4K4PIM1PIM3PIM2MINK1
SCHEMBL30734190 0.74 MAPT (0.44) MEN1KMT2AALDH1A1GAAMAPT
SCHEMBL30734233 0.72 ACHE (0.55) MAP4K4MEN1KMT2AALDH1A1MAPT
SCHEMBL30734187 0.71 ACHE (0.53) MEN1KMT2AALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382301-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF UNIV ARIZONA (US) 2025-12-18 US disclosed
EP-4543888-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF Arizona Board of Regents on behalf of The University of Arizona (US) 2025-04-30 EP disclosed
WO-2023250083-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2023-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382301-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF CLK2, CLK3, CLK1 MAP4K4 107/4885PIM1 1103/4885PIM3 855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.